Drug General Information
Drug ID
Former ID
Drug Name
Indication Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] Phase 1 [1]
Merck KGaA
Target and Pathway
Target(s) Proto-oncogene c-Met (MET) Target Info Inhibitor [2]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Axon guidance
Focal adhesion
Adherens junction
Bacterial invasion of epithelial cells
Epithelial cell signaling in Helicobacter pylori infection
Pathways in cancer
Transcriptional misregulation in cancer
Proteoglycans in cancer
MicroRNAs in cancer
Renal cell carcinoma
Central carbon metabolism in cancer
Pathway Interaction Database Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
Arf6 signaling events
Signaling events mediated by TCPTP
Posttranslational regulation of adherens junction stability and dissassembly
Direct p53 effectors
Syndecan-1-mediated signaling events
Stabilization and expansion of the E-cadherin adherens junction
a6b1 and a6b4 Integrin signaling
FGF signaling pathway
Regulation of retinoblastoma protein
Reactome Sema4D mediated inhibition of cell attachment and migration
WikiPathways TGF beta Signaling Pathway
Signaling of Hepatocyte Growth Factor Receptor
Focal Adhesion
Extracellular vesicle-mediated signaling in recipient cells
Signaling Pathways in Glioblastoma
miR-targeted genes in squamous cell - TarBase
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in epithelium - TarBase
Semaphorin interactions
REF 1 ClinicalTrials.gov (NCT01110083) First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
REF 2 2012 ASCO Annual Meeting.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.